Login / Signup

The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.

Kate D LynchSatish KeshavRoger W Chapman
Published in: Current hepatology reports (2019)
Anti-TNF antibodies may benefit PSC when used to treat concomitant IBD, and this may be a direct effect on the liver in a subgroup of patients, or may be an indirect effect of treating IBD. Similarly, anti-integrin therapy may benefit a subset of patients with IBD and PSC. RCTs could decide the role of emerging biologics in PSC, although future trials should be guided by biomarkers that could predict response to the pathway being targeted.
Keyphrases